Advertisement

Ovarian Cancer pp 155-159 | Cite as

Establishment of Ovarian Cancer Cell Lines

  • Simon P. Langdon
  • Sandra S. Lawrie
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 39)

Abstract

Human tumor cell lines have provided valuable model systems to study a wide variety of tumor characteristics including the cell biology, genetics, and chemosensitivity profiles of disease. A large number of ovarian cancer cell lines have now been established and are in widespread use Table 1) (1-15). Many of these have been selected to reflect specific situations, e.g., pre- and postchemotherapy models or different histo- logical subtypes.
Table 1

Properties of Established Ovarian Carcinoma Cell Lines

   

Prior

 

Cell Line

Histology

Source

Treatment

Ref.

PE01

P.D. Serous adenoca

Ascites

P/FU/CHL

1

PE04

P.D. Serous adenoca

Ascites

P/FU/CHL

1

PE06

P.D. Serous adenoca

Ascites

P/FU/CHL

2

PEA1

P.D. Adenoca

Pleural

None

2

PEA2

P.D. Adenoca

Ascites

P/Pred

2

PE016

P.D. Serous adenoca

Ascites

Radioth

2

PE014

W.D.Serous adenoca

Ascites

None

2

T014

W.D.Serous adenoca

Sol. Met

None

2

PE023

W.D.Serous adenoca

Ascites

P/CHL

2

SKOV-3

Adenoca

Ascites

T

3

SW626

Adenoca

3

OVCAR-2

Adenoca

Ascites

P/Cy

4

OVCAR-3

P.D. papillary adenoca

Ascites

P/Cy/Adr

5

OVCAR-4

Adenoca

Ascites

P/Cy/Adr

6

OVCAR-5

Adenoca

Ascites

None

7

OAW 28

Adenoca

Ascites

P / Mel

8

OAW 42

Serous adenoca

Ascites

P

8

41M

Adenoca

Ascites

None

9

59M

Endometr adenoca

Ascites

None

8

CH1

Papillary adenoca

Ascites

P/ JM8

8

138D

Serous adenoca

Ascites

Carb

9

180D

Adenoca

Ascites

P

9

200D

Serous adenoca

Solid

None

9

253D

Serous adenoca

Ascites

Cy/MPA

9

HOC-1

W.D. Serous adenoca

Ascites

None

10

HOC-7

W.D. Serous adenoca

Ascites

None

10

CAOV-3

Adenoca

Tumour

Cy/Adr/FU

10

COLO 110

Serous adenoca

Sol. Met

None

11

COLO 316

Serous adenoca

Pleural

None

11

COLO 319

Serous adenoca

Ascites

None

11

COLO 330

Serous adenoca

Ascites

Mel/Radiother

11

IGROV1

Adenoca

Primary

None

12

HTOA

W.D. serous adenoca

Primary

None

13

OV-1063

Papillary adenoca

Ascites

Cy/Adr/P/HMM

14

DO-s

W.D. mucinous adenoca

Ascites

15

P.D. = Poorly differentiated; W.D. = Well differentiated; adenoca = adenocarcinoma; pleural = pleural effusion; Sol.met. = solid metastasis; P = cisplatin; FU = 5-fluorouracil; CHL = chlorambucil; Pred = prednimustine; Radioth = radiotherapy; T = thiotepa; Cy = cyclophosphamide; Adr = adriamycin; Mel = melphalan; Carb = carboplatin; MPA = medroxyprogesterone actetate; HMM = examethylmelamine.

Keywords

Mesothelial Cell Ovarian Cancer Patient Ovarian Cancer Cell Line Human Tumor Cell Line Initial Culture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wolf, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McIntyre, M. A., Adams, D. J., et al. (1987) Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int. J. Cancer 39, 695–702.CrossRefPubMedGoogle Scholar
  2. 2.
    Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A., Hayward, I. P., et al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 48, 6166–6172.PubMedGoogle Scholar
  3. 3.
    Fogh, J., Fogh, J. M., and Orfeo, T. (1977) One hundred and twenty seven cultured tumour cell lines producing tumours in nude mice. J. Natl. Cancer Inst. 59, 221-226Google Scholar
  4. 4.
    Pirker, R., FitzGerald, D. J., Hamilton, T. C., Ozols, R. F., Laird, W., Frankel, A. E., et al. (1985) Characterization of immunotoxins active against ovarian cancer cell lines. J. Clin. Invest. 76, 1261–1267.CrossRefGoogle Scholar
  5. 5.
    Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., et al. (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43, 5379–5389.PubMedGoogle Scholar
  6. 6.
    Louie, K. G., Behrens, B. C., Kinsella, T. J., Hamilton, T. C., Grotzinger, K. R., McKoy, W. M., et al. (1985) Radiation survival parameters of antineoplastic drug-sensitive and-resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 45, 2110–2115.PubMedGoogle Scholar
  7. 7.
    Louie, K. G., Hamilton, T. C., Winker, M. A., Behrens, B. C., Tsuruo, T., Klecker, R. W., et al. (1986) Adriamycin accumulation and metabolism in adriamycin-sensitive and-resistant human ovarian cancer cell lines. Biochem. Pharmacol. 35, 467–472.CrossRefPubMedGoogle Scholar
  8. 8.
    Hills, C. A., Kelland, L. R., Abel, G., Siracky, J., Wilson, A. P., and Harrap, K. R. (1989) Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer 59, 527–534.CrossRefPubMedGoogle Scholar
  9. 9.
    Wilson, A. P., Dent, M., Pelovic, T., Hubbold, L., and Radford, H. (1996) Characterisation of seven human ovarian tumour cell lines. Br. J. Cancer 74, 722–727.CrossRefPubMedGoogle Scholar
  10. 10.
    Buick, R. N., Pullano, R., and Trent, J. M. (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45, 3668–3676.PubMedGoogle Scholar
  11. 11.
    Woods, L. K., Morgan, R. T., Quinn, L. A., Moore, G. E., Semple, T. U., and Stedman, K. E. (1979) Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res. 39, 4449–459.PubMedGoogle Scholar
  12. 12.
    Benard, J., Da Silva, J., De Bois, M-C., Boyer, P., Duvillard, P., Chiric, E., et al. (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 45, 4970–4979.PubMedGoogle Scholar
  13. 13.
    Ishiwata, I., Ishiwata, C., Soma, M., Nozawa, S., and Ishikawa, H. (1987) Characterization of newly established human ovarian carcinoma cell line-Special reference of the effects of cis-platinum on cellular proliferation and release of CA125. Gynecol. Oncol. 26, 340-354.Google Scholar
  14. 14.
    Horowitz, A. T., Treves, A. J., Voss, R., Okon, E., Fuks, Z., Davidson, L., et al. (1985) A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers. Oncology 42, 332–337.CrossRefPubMedGoogle Scholar
  15. 15.
    Briers, T. W., Stroobants, P., Vandeputte, T. M., Nouwen, E. J., Conraads, M. V., Eestermans, G., et al. (1989) Establishment and characterization of a human ovarian neoplastic cell line DO-s. Cancer Res. 49, 5153–5161.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Simon P. Langdon
    • 1
  • Sandra S. Lawrie
    • 1
  1. 1.Imperial Cancer Research Fund, Medical Oncology UnitWestern General HospitalEdinburghScotland

Personalised recommendations